Summary
My background is as a chromatin biologist, and I’m interested in understanding the mechanisms that control gene expression, focussing on how they are dysregulated in multiple myeloma. I hold a Kay Kendall Leukaemia Fund Intermediate Fellowship, through which I am exploring the role of spontaneous chromatin changes in the evolution of drug resistance in multiple myeloma. My fellowship is focussed on exploring the epigenetic changes that happen during relapse to understand how drug resistance can arise without requiring genetic mutations – and finding therapeutic targets to reverse this.
Selected Publications
Journal Articles
Crump NT, Smith AL, Godfrey L, et al., 2023, MLL-AF4 cooperates with PAF1 and FACT to drive high-density enhancer interactions in leukemia, Nature Communications, Vol:14, ISSN:2041-1723, Pages:1-20
Crump NT, Hadjinicolaou A, Xia M, et al., 2021, Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation, Cell Reports, Vol:35, ISSN:2211-1247
Crump NT, Ballabio E, Godfrey L, et al., 2021, BET inhibition disrupts transcription but retains enhancer-promoter contact, Nature Communications, Vol:12, ISSN:2041-1723
Godfrey L, Crump NT, O'Byrne S, et al., 2021, H3K79me2/3 controls enhancer–promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells, Leukemia, Vol:35, ISSN:0887-6924, Pages:90-106